RT Journal Article
SR Electronic
T1 Variants in SARS-CoV-2 Associated with Mild or Severe Outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.01.20242149
DO 10.1101/2020.12.01.20242149
A1 Jameson D. Voss
A1 Martin Skarzynski
A1 Erin M. McAuley
A1 Ezekiel J. Maier
A1 Thomas Gibbons
A1 Anthony C. Fries
A1 Richard R. Chapleau
YR 2020
UL http://medrxiv.org/content/early/2020/12/03/2020.12.01.20242149.abstract
AB Introduction The coronavirus disease 2019 (COVID-19) pandemic is a global public health emergency causing a disparate burden of death and disability around the world. The molecular characteristics of the virus that predict better or worse outcome are largely still being discovered.Methods We downloaded 155,958 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes from GISAID and evaluated whether variants improved prediction of reported severity beyond age and region. We also evaluated specific variants to determine the magnitude of association with severity and the frequency of these variants among the genomes.Results Logistic regression models that included viral genomic variants outperformed other models (AUC=0.91 as compared with 0.68 for age and gender alone; p<0.001). Among individual variants, we found 17 single nucleotide variants in SARS-CoV-2 have more than two-fold greater odds of being associated with higher severity and 67 variants associated with ≤ 0.5 times the odds of severity. The median frequency of associated variants was 0.15% (interquartile range 0.09%-0.45%). Altogether 85% of genomes had at least one variant associated with patient outcome.Conclusion Numerous SARS-CoV-2 variants have two-fold or greater association with odds of mild or severe outcome and collectively, these variants are common. In addition to comprehensive mitigation efforts, public health measures should be prioritized to control the more severe manifestations of COVID-19 and the transmission chains linked to these severe cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded/supported by the United States Air Force, Air Force Research Laboratory, 711 HPW, Wright Patterson, AFB. Contract Support was provided by Booz Allen Hamilton.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A -- public data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from GISAID. The shell scripts used for variant alignment and variant calling, along with the Python scripts used to perform the steps described in the manuscript should be accessed on GitHub at https://github.com/mskar/variants https://www.gisaid.org/ https://github.com/mskar/variants